KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 99 filers reported holding KEROS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,397 | -8.3% | 1,424 | +15.6% | 0.00% | 0.0% |
| Q2 2023 | $49,502 | +11.3% | 1,232 | +18.2% | 0.00% | 0.0% |
| Q1 2023 | $44,493 | -22.2% | 1,042 | -12.5% | 0.00% | -33.3% |
| Q4 2022 | $57,192 | +40.4% | 1,191 | +10.0% | 0.00% | +50.0% |
| Q3 2022 | $40,742 | +36.2% | 1,083 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $29,923 | -49.2% | 1,083 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $58,894 | -75.3% | 1,083 | -73.5% | 0.00% | -33.3% |
| Q4 2021 | $238,838 | +47.9% | 4,082 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $161,484 | -6.9% | 4,082 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $173,363 | -26.1% | 4,082 | +7.1% | 0.00% | -50.0% |
| Q1 2021 | $234,629 | -12.7% | 3,812 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $268,898 | +165.0% | 3,812 | +44.9% | 0.00% | +100.0% |
| Q3 2020 | $101,478 | +2.8% | 2,631 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $98,689 | – | 2,631 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
| First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
| Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
| Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
| Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
| Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
| CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
| Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
| Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
| Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |